関節リウマチ治療薬の世界市場:DMARD、NSAID、コルチコステロイド、鎮痛薬

◆英語タイトル:Global Rhematoid Arthritis Drugs Market 2016-2020
◆商品コード:IRTNTR8751
◆発行会社(調査会社):Technavio
◆発行日:2016年2月17日
◆ページ数:126
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,500 ⇒換算¥399,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥513,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、関節リウマチ治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、関節リウマチ治療薬の世界市場規模及び予測、種類別分析、剤形別分析、薬剤種類別分析、市場シェア、地域別分析/市場規模、主要国別分析、購買基準、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About Rheumatoid Arthritis Drugs

RA is a chronic inflammatory autoimmune disease seen in people aged between 30 and 60 years. The symptoms of the disease appear slowly, with mild pain around the joints coupled with stiffness and fatigue. In the later stages, it causes inflammation of the joints. Genetic and environmental elements are known to contribute to the development of the condition. DMARDs, NSAIDs, corticosteroids, and analgesics are being developed and administered to treat individuals with RA.

Technavio’s analysts forecast the global RA drugs market to grow at a CAGR of 3.43% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global RA drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat the disease.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Rheumatoid Arthritis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AbbVie
• Amgen
• Bristol-Myers Squibb (BMS)
• Johnson & Johnson
• Pfizer
• F. Hoffmann-La Roche

[Other prominent vendors]
• Ablynx
• Alder BioPharmaceuticals
• Antares Medical Services
• Astellas Pharma
• AstraZeneca
• Boehringer Ingelheim
• Can-Fite BioPharma
• Celgene
• Celltrion
• ChemoCentryx
• Eisai
• Eli Lilly
• Gilead Sciences
• GlaxoSmithKline
• Incyte
• KaloBios Pharmaceuticals
• Lexicon Pharmaceuticals
• Merck
• Morphotek
• Novo Nordisk
• Regeneron Pharmaceuticals
• Sandoz
• Sanofi
• Santarus
• Takeda Pharmaceuticals
• UCB
• Vertex Pharmaceuticals

[Market driver]
• Growing older population
• For a full, detailed list, view our report

[Market challenge]
• Increasing costs of biologicals
• For a full, detailed list, view our report

[Market trend]
• Emergence of biosimilars
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding RA
• Etiology and pathophysiology
• Signs and symptoms
• Diagnosis
• Disease management
• Economic burden of RA
• Epidemiology

PART 06: Impact of biologics in RA

PART 07: Pipeline portfolio
• Novel mechanisms targeted by pipeline candidates
• Clinical trials for RA

PART 08: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 09: Market segmentation by drug class
• DMARDs
• NSAIDs
• Corticosteroids
• Analgesics
• Others
• Global DMARDs market
• Global NSAIDs market
• Global corticosteroids market
• Global analgesics market

PART 10: Market segmentation by MOA
• TNF inhibitors
• IL-1 blockers
• JAK inhibitors
• Selective costimulation modulators

PART 11: Market segmentation by type of molecule
• Biologics
• Small molecules

PART 12: Market segmentation by ROA
• Oral
• Parenteral
• Topical

PART 13: Market segmentation by dosage form
• Solid
• Liquid
• Semi-solid

PART 14: Geographical segmentation
• RA drugs market in Americas
• RA drugs market in US
• RA drugs market in EMEA
• RA drugs market in Germany
• RA drugs market in UK
• RA drugs market in Spain
• RA drugs market in Italy
• RA drugs market in France
• Rheumatoid arthritis drugs market in APAC
• RA drugs market in Japan
• RA drugs market in Australia
• RA drugs market in India
• RA drugs market in China

PART 15: Key leading countries

PART 16: Market drivers
• Growing older population
• Market dominance of biologics
• Promising drug pipeline
• Changing lifestyle patterns
• Advances in diagnosis technology

PART 17: Impact of drivers

PART 18: Market challenges
• Increasing costs of biologicals
• Loss of patent exclusivity of branded therapies
• Use of complementary and alternative medicines (CAMs)
• Adverse effects of drugs
• Stringent regulations

PART 19: Impact of drivers and challenges

PART 20: Market trends
• Emergence of biosimilars
• Patient assistance programs
• Popularity of off-label and traditional treatment options
• Strategic alliances
• Increase in public awareness

PART 21: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• AbbVie
• Amgen
• BMS
• F. Hoffmann-La Roche
• Johnson & Johnson
• Pfizer
• Other prominent vendors

PART 22: Appendix4
• List of abbreviations4

PART 23: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for RA drugs
Exhibit 03: Classification of RA based on disease severity
Exhibit 04: Classification of RA based on disease severity 2016
Exhibit 05: Etiology and pathophysiology of RA
Exhibit 06: Signs and symptoms of RA
Exhibit 07: Diagnostic tests for RA
Exhibit 08: Treatment options for RA
Exhibit 09: Non-pharmacological therapies used for RA
Exhibit 10: Pharmacotherapy therapy for RA
Exhibit 11: Drugs used to treat RA
Exhibit 12: Classification of surgical treatment for RA
Exhibit 13: Percentage share of treatment of RA 2016
Exhibit 14: Historical milestones in treatment of RA
Exhibit 15: Treatment algorithm for RA
Exhibit 16: Economic burden of RA
Exhibit 17: Annual treatment costs of RA within Europe and US 2015 ($)
Exhibit 18: Cost difference between biological DMARDs and non-biological DMARDs
Exhibit 19: Projected prevalence of RA in Americas 2010-2030 ($ millions)
Exhibit 20: New cases of RA in UK per year 2016
Exhibit 21: Existing cases of RA in UK
Exhibit 22: Impact of biologics on various sectors
Exhibit 23: Pipeline molecules for RA
Exhibit 24: Novel targets of pipeline candidates
Exhibit 25: Candidates under development: Baricitinib
Exhibit 26: Candidates under development: Decernotinib
Exhibit 27: Candidates under development: CCX354
Exhibit 28: Candidates under development: Sirukumab
Exhibit 29: Candidates under development: Infliximab biosimilar
Exhibit 30: Candidates under development: Secukinumab
Exhibit 31: Candidates under development: Bimekizumab
Exhibit 32: Clinical trials of RA drugs by phase 2016
Exhibit 33: Clinical trials of RA drugs by status 2016
Exhibit 34: Global RA drugs market 2015-2020 ($ billions)
Exhibit 35: Opportunities in RA drugs industry
Exhibit 36: Five forces analysis
Exhibit 37: Global RA drugs market segmentation by drug class
Exhibit 38: Examples of non-biologic DMARDs and biologic DMARDs for RA
Exhibit 39: NSAIDs used to treat RA
Exhibit 40: Market share of global RA drugs market by drug class 2015
Exhibit 41: Global DMARDs market 2015-2020 ($ billions)
Exhibit 42: Global NSAIDs market 2015-2020 ($ billions)
Exhibit 43: Global corticosteroids market 2015-2020 ($ billions)
Exhibit 44: Global analgesics market 2015-2020 ($ billions)
Exhibit 45: Market segmentation of global RA drugs market by MOA
Exhibit 46: Mean percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 47: Global RA drugs market share by MOA 2015
Exhibit 48: Global RA drugs market segmentation by type of molecule
Exhibit 49: Global RA drugs market share by type of molecules 2015
Exhibit 50: Global RA drugs market segmentation by ROA
Exhibit 51: Global RA drugs market segmentation by ROA 2015
Exhibit 52: Global RA drugs market segmentation by dosage form
Exhibit 53: Global RA drugs market segmentation by dosage form 2015
Exhibit 54: Global RA drugs by geography 2015
Exhibit 55: Global RA drugs market by geography 2015-2020 ($ billions)
Exhibit 56: Global RA drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 57: RA drugs market in Americas 2015-2020 ($ billions)
Exhibit 58: RA drugs market in Americas by country 2015
Exhibit 59: RA drugs market in US 2015-2020 ($ billions)
Exhibit 60: RA drugs sales in US by drug class 2015
Exhibit 61: Drivers and challenges of RA drugs market in US
Exhibit 62: RA drugs market in EMEA 2015-2020 ($ billions)
Exhibit 63: RA drugs market in EMEA by country 2015
Exhibit 64: RA sales in EMEA by drug class 2015
Exhibit 65: RA drugs market in Germany 2015-2020 ($ billions)
Exhibit 66: RA drugs market in UK 2015-2020 ($ billions)
Exhibit 67: RA drugs market in Spain 2015-2020 ($ millions)
Exhibit 68: RA drugs market in Italy 2015-2020 ($ millions)
Exhibit 69: RA drugs market in France 2015-2020 ($ millions)
Exhibit 70: RA drugs market in APAC 2015-2020 ($ billions)
Exhibit 71: RA drugs market in APAC by country 2015
Exhibit 72: RA drugs market in Japan 2015-2020 ($ billions)
Exhibit 73: RA drugs sales in Japan by drug class 2015
Exhibit 74: Drivers and challenges to growth of RA drugs market in Japan
Exhibit 75: RA drugs market in Australia 2015-2020 ($ millions)
Exhibit 76: RA drugs sales in Australia by drug class 2015
Exhibit 77: Drivers and challenges in RA drugs market in Australia
Exhibit 78: RA drugs market in India 2015-2020 ($ billions)
Exhibit 79: RA sales in India by drug class 2015
Exhibit 80: RA drugs market in China 2015-2020 ($ millions)
Exhibit 81: RA drugs sales in China by drug class 2015
Exhibit 82: Key leading countries
Exhibit 83: Population aged 60 years and over: World, developed and developing regions ($ millions)
Exhibit 84: FDA approval of biologicals
Exhibit 85: List of pipeline molecules
Exhibit 86: Lifestyle factors – Risk of rheumatoid arthritis
Exhibit 87: Impact of drivers
Exhibit 88: Average annual treatment cost of Humira, Enbrel, and Remicade 2014 ($)
Exhibit 89: Approval and patent expiries of top selling biologics
Exhibit 90: CAM therapies for RA
Exhibit 91: Usage of CAM in US
Exhibit 92: Side effects associated with RA
Exhibit 93: Impact of drivers and challenges
Exhibit 94: Patient assistance programs offered by companies
Exhibit 95: Revenue share of RA drugs by vendors 2015
Exhibit 96: YoY sales comparison of top drugs 2012-2014 ($ billions)
Exhibit 97: Competitive assessment of top RA drugs
Exhibit 98: Revenue share of RA drugs 2015
Exhibit 99: AbbVie: Product segmentation by revenue 2014
Exhibit 100: AbbVie: YoY revenue and growth rate of Humira 2012-2014 ($ billions)
Exhibit 101: AbbVie: YoY revenue and growth rate of Humira (in US) 2012-2014 ($ billions)
Exhibit 102: AbbVie: YoY revenue and growth rate of Humira (ROW) 2012-2014 ($ billions)
Exhibit 103: Sales of Humira in major markets
Exhibit 104: AbbVie: SWOT analysis
Exhibit 105: Amgen: YoY revenue and growth rate of Enbrel (in US and Canada) 2012-2014 ($ billions)
Exhibit 106: Amgen: YoY revenue and growth rate of Enbrel (in US) 2012-2014 ($ billions)
Exhibit 107: Amgen: YoY revenue and growth rate of Enbrel (in Canada) 2012-2014 ($ millions)
Exhibit 108: Amgen: SWOT analysis
Exhibit 109: BMS: Segmentation by revenue 20141
Exhibit 110: BMS: YoY revenue and growth rate of Orencia 2012-2014 ($ billions)
Exhibit 111: BMS: YoY revenue and growth rate of Orencia (in US) 2012-2014 ($ millions)
Exhibit 112: BMS: YoY revenue and growth rate of Orencia (ROW) 2012-2014 ($ millions)
Exhibit 113: Orencia sales for RA in major markets 2014
Exhibit 114: BMS: SWOT analysis
Exhibit 115: RA products by revenue 2014
Exhibit 116: F. Hoffmann-La Roche: YoY growth and revenue generated from product sales of MabThera/Rituxan 2011-2014 ($ billions)
Exhibit 117: MabThera/Rituxan geographic segmentation by revenue 2014
Exhibit 118: F.Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2012-2014 ($ millions)
Exhibit 119: Actemra/RoActemra geographic segmentation by revenue 2014
Exhibit 120: F. Hoffmann-La Roche: SWOT analysis
Exhibit 121: Johnson & Johnson: Segmentation of key drugs 2014
Exhibit 122: Johnson & Johnson: YoY growth rate and revenue of Remicade 2012-2014 ($ billions)
Exhibit 123: Johnson & Johnson: YoY growth rate and revenue of Remicade (in US) 2012-2014 ($ billions)
Exhibit 124: Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2012-2014 ($ billions)
Exhibit 125: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2012-2014 ($ millions)
Exhibit 126: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (in US) 2012-2014 ($ millions)
Exhibit 127: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (ROW) 2012-2014 ($ millions)
Exhibit 128: Johnson & Johnson: SWOT analysis
Exhibit 129: Pfizer: Rhematoid drugs product segmentation by revenue 2014
Exhibit 130: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2012-2014 ($ billions)
Exhibit 131: Pfizer: YoY revenue and growth rate of Celebrex 2012-2014 ($ billions)
Exhibit 132: Pfizer: YoY revenue and growth rate of Xeljanz 2012-2014 ($ billions)
Exhibit 133: Pfizer: SWOT analysis



【掲載企業】

AbbVie, Amgen, Bristol-Myers Squibb (BMS), Johnson & Johnson, Pfizer, F. Hoffmann-La Roche, Ablynx, Alder BioPharmaceuticals, Antares Medical Services, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celltrion, ChemoCentryx, Eisai, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Incyte, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Merck, Morphotek, Novo Nordisk, Regeneron Pharmaceuticals, Sandoz, Sanofi, Santarus, Takeda Pharmaceuticals, UCB, Vertex Pharmaceuticals.

【レポートのキーワード】

関節リウマチ治療薬、医薬品、DMARD、NSAID、コルチコステロイド、鎮痛薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[関節リウマチ治療薬の世界市場:DMARD、NSAID、コルチコステロイド、鎮痛薬]販売に関する免責事項
★調査レポート[関節リウマチ治療薬の世界市場:DMARD、NSAID、コルチコステロイド、鎮痛薬]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆